GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Additional Paid-In Capital

AbCellera Biologics (STU:8QQ) Additional Paid-In Capital : €130.83 Mil(As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Additional Paid-In Capital?


AbCellera Biologics's quarterly additional paid-in capital increased from Dec. 2023 (€111.01 Mil) to Mar. 2024 (€117.75 Mil) and increased from Mar. 2024 (€117.75 Mil) to Jun. 2024 (€130.83 Mil).

AbCellera Biologics's annual additional paid-in capital increased from Dec. 2021 (€31.29 Mil) to Dec. 2022 (€69.97 Mil) and increased from Dec. 2022 (€69.97 Mil) to Dec. 2023 (€111.01 Mil).

AbCellera Biologics Additional Paid-In Capital Historical Data

The historical data trend for AbCellera Biologics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Additional Paid-In Capital Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 2.07 4.87 31.29 69.97 111.01

AbCellera Biologics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.00 102.49 111.01 117.75 130.83

AbCellera Biologics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

AbCellera Biologics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Additional Paid-In Capital
Comparable Companies
AGIO MRUS SAGE RCUS CVAC RYZB ZNTL AMLX CLDX EQRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ABCL:USA 8QQ:Germany
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
Website
https://www.abcellera.com
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Headlines

No Headlines